Pangen Biotech (222110) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, Pangen Biotech (222110) reported revenue of 13.4 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
202513.4 billion KRW1.5 billion KRW2.1 billion KRW[source]
202414.7 billion KRW1.0 billion KRW944 million KRW[source]
20237.3 billion KRW-4.2 billion KRW-4.5 billion KRW[source]
20226.5 billion KRW-4.6 billion KRW-4.5 billion KRW[source]
20217.9 billion KRW-3.3 billion KRW-3.3 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
202532.7 billion KRW2.8 billion KRW29.9 billion KRW[source]
202430.5 billion KRW5.6 billion KRW24.9 billion KRW[source]
202320.7 billion KRW8.2 billion KRW12.6 billion KRW[source]
202220.7 billion KRW3.5 billion KRW17.2 billion KRW[source]
202143.3 billion KRW22.2 billion KRW21.1 billion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice